<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Jiafeng Gu</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Determinants of biopharmaceutical R&amp;amp;D expenditures in China: the impact of spatiotemporal context</style></title><secondary-title><style face="normal" font="default" size="100%">Scientometrics</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://link.springer.com/article/10.1007/s11192-021-04058-y</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">126</style></volume><pages><style face="normal" font="default" size="100%">6659–6680</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">The spatiotemporal context a ects corporate behavior because any corporate activity is carried out in a speci c time and space. Based on an examination on the research and development (R&amp;amp;D) expenditures of 284 listed biopharmaceutical companies in China, this study nds that the innovation space of the biopharmaceutical industry presents a spa- tial “North–South” pattern. The spatial gravity center of the biopharmaceutical industry’s R&amp;amp;D investment has been shifting to the eastern coastal region. This spatiotemporal con- text will impact the R&amp;amp;D investment of biopharmaceutical companies. Research shows that the distance between biopharmaceutical companies and the gravity center has a direct impact on the R&amp;amp;D expenditures of biopharmaceutical companies. This study supports the context-sensitive thesis and shows how the spatiotemporal context a ects the R&amp;amp;D invest- ment of biopharmaceutical companies while controlling rm-level factors.</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>